

HBV Forum 15 Meeting

Thursday, November 6, 2025

National Union Building

918 F Street, Northwest

Washington, DC 20004

*Denotes remote participation

12:00 PM	Registration and Lunch	
1:30 PM	Introductory Remarks and Program Overview	
1:30 PM	Welcome, Forum Updates, Program Overview, and Acknowledgments	<i>Ekene Osakwe, Forum for Collaborative Research</i>
1:35 PM	Steering Committee Co-Chair Welcoming Remarks	<i>Veronica Miller, Forum for Collaborative Research</i>
		<i>Terry Wright</i>
		<i>Norah Terrault, Keck School of Medicine of USC</i>
1:40 PM	Session I: Roundtable Updates	
	Moderators: Veronica Miller, Forum for Collaborative Research & Norah Terrault, Keck School of Medicine of USC	
1:40 PM	Rapid Fire Industry Updates	<i>Sue Currie, Virion Therapeutics</i>
		<i>Emily Harrison, Precision BioSciences</i>
		<i>Kendra Congdon, Tune Therapeutics</i>
		<i>Tracy McGregor, nChroma Bio</i>
1:55 PM	EMA Updated Guidelines	<i>*Stephanie Buchholz, European Medicines Agency</i>
2:05 PM	HBV/MASLD Working Group Update	<i>Harry Janssen, Erasmus University Medical Center</i>
2:15 PM	Asian HBV/HDV Endpoints Consensus Meeting Update	<i>Veronica Miller, Forum for Collaborative Research</i>
2:20 PM	Open Discussion	<i>All Meeting Participants</i>

2:40 PM	Session II: Hepatitis Delta Therapeutics and Assay Development	
	Moderators: Pietro Lampertico, University of Milan & Wendy Spearman, University of Cape Town	
2:40 PM	Feedback from Delta Cure	<i>Pietro Lampertico, University of Milan</i>
2:45 PM	Industry Updates: HDV Therapies and Diagnostics	<i>Todd Corell, Vir Biotechnology</i>
		<i>Nancy Shulman, Blue Jay Therapeutics</i>
		<i>Marc Windisch, Assembly Biosciences</i>
		<i>Jenny Stanton, Gilead Sciences</i>
		<i>Jeffrey Glenn, Stanford University</i>
		<i>Christian Voitenleitner, Roche Diagnostics International</i>
		<i>Gerald Wallweber, Labcorp/Monogram Biosciences</i>
3:20 PM	Panel Discussion/Open Discussion	<i>All Speakers +</i>
		<i>Jessica Hicks, World Hepatitis Alliance</i>
		<i>Audience</i>
4:00 PM	Break	
4:25 PM	Session III: Hepatocellular Carcinoma	
	Moderators: Terry Wright & Robert Gish, Robert G Gish Consultants LLC	
4:25 PM	Why HCC? Why Now? (Opening Remarks)	<i>*Loey Lung-Yi Mak, The University of Hong Kong</i>
4:30 PM	Global HCC Epidemiology, Changing Risk Patterns, and Unmet Medical Needs	<i>Robert Wong, Stanford University School of Medicine</i>
4:45 PM	Industry Updates: Biomarkers	<i>Shivani Mahajan, Helio Genomics</i>
		<i>Elle Grevstad, Exact Sciences</i>
		<i>Timothy Block, Baruch S. Blumberg Institute</i>
5:00 PM	Panel Discussion/Open Discussion	<i>All Speakers +</i>
		<i>Mark Sonderup, University of Cape Town</i>
		<i>*Alexander Stockdale, University of Liverpool</i>
		<i>Yasmin Ibrahim, Hepatitis B Foundation</i>
		<i>Audience</i>

5:30 PM	Session IV: Gene Editing and Epigenomics	
	Moderators: Ed Gane, University of Auckland & Fabien Zoulim, Lyon Hepatology Institute	
5:30 PM	Perspectives and Challenges in <i>in vivo</i> Gene Therapy for HBV: Building a Clinical Program from First-in-Human Trials to a One-and-Done CURE	Ed Gane, University of Auckland
5:45 PM	Panel Discussion/Open Discussion	Emily Harrison, Precision BioSciences
		Kendra Congdon, Tune Therapeutics
		Tracy McGregor, nChroma Bio
		Bob Zhang, Epigenic Therapeutics
		Man-Fung Yuen, The University of Hong Kong
		Mark Sulkowski, John Hopkins University School of Medicine
		Audience
6:25 PM	Meeting Wrap Up and Adjourn	
6:30 PM	HBV, Liver, and PSC Forums Networking Reception	